KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Receivables - Net: 2018-2024

Historic Receivables - Net for Castle Biosciences (CSTL) over the last 7 years, with Dec 2024 value amounting to $51.2 million.

  • Castle Biosciences' Receivables - Net fell 1.55% to $49.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.5 million, marking a year-over-year decrease of 1.55%. This contributed to the annual value of $51.2 million for FY2024, which is 33.72% up from last year.
  • As of FY2024, Castle Biosciences' Receivables - Net stood at $51.2 million, which was up 33.72% from $38.3 million recorded in FY2023.
  • In the past 5 years, Castle Biosciences' Receivables - Net registered a high of $51.2 million during FY2024, and its lowest value of $12.8 million during FY2020.
  • Moreover, its 3-year median value for Receivables - Net was $38.3 million (2023), whereas its average is $37.7 million.
  • As far as peak fluctuations go, Castle Biosciences' Receivables - Net fell by 12.90% in 2020, and later surged by 63.15% in 2023.
  • Yearly analysis of 5 years shows Castle Biosciences' Receivables - Net stood at $12.8 million in 2020, then skyrocketed by 35.45% to $17.3 million in 2021, then soared by 35.84% to $23.5 million in 2022, then spiked by 63.15% to $38.3 million in 2023, then spiked by 33.72% to $51.2 million in 2024.